Yes, we report on that.
Our companies do not report to the PMPRB, the Patented Medicine Prices Review Board, as the patent drug companies do, but it's in the range of about 12% to 14% of our revenue. The reason for that and why it's actually higher than the patent holding companies is that a lot of the development is actually done in Canada. There are large manufacturers, like Apotex and Pharmascience, that are Canadian-based companies. Apotex has been the largest spender on research and development in pharmaceuticals for many years.